An affordable HIV-1 drug resistance monitoring method for resource limited settings
about
Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.Implementing antiretroviral resistance testing in a primary health care HIV treatment programme in rural KwaZulu-Natal, South Africa: early experiences, achievements and challenges.Evidence of long-lived founder virus in mother-to-child HIV transmission.Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges.HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing.Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa.HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe.Implementation of a point mutation assay for HIV drug resistance testing in Kenya
P2860
Q33712438-F5EC51C5-3351-424B-876C-E1FC300803B6Q34997577-3D4099A1-4F67-49FC-9D1B-3180C64B1B63Q35114102-E307FCEA-1557-48BE-BF17-D245B547097DQ35203401-6F3CDBD8-105F-4915-AA0A-2441A86633DCQ35868716-D7C2AACA-2F6D-422C-90DE-7F7E41BC8689Q37336600-E236DFA0-5A5C-48AA-90CF-DBCECBA5ADF7Q37634044-92E862B2-9A92-47D1-9808-ACF56052F8C3Q38375479-B0DC8FF6-BD68-48E5-AEA8-2996BAA70CDBQ39209322-76A8F8B6-8A84-4121-B1D1-BA056BCCC6D5Q50052129-E47D3DBB-DDEF-4AF4-94E1-5D6D04675E74Q57131360-1CDB7014-75D1-4E64-9E17-665E914766FE
P2860
An affordable HIV-1 drug resistance monitoring method for resource limited settings
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
An affordable HIV-1 drug resistance monitoring method for resource limited settings
@ast
An affordable HIV-1 drug resistance monitoring method for resource limited settings
@en
type
label
An affordable HIV-1 drug resistance monitoring method for resource limited settings
@ast
An affordable HIV-1 drug resistance monitoring method for resource limited settings
@en
prefLabel
An affordable HIV-1 drug resistance monitoring method for resource limited settings
@ast
An affordable HIV-1 drug resistance monitoring method for resource limited settings
@en
P2093
P2860
P356
P1476
An affordable HIV-1 drug resistance monitoring method for resource limited settings
@en
P2093
Charity Mkhize
Christopher Seebregts
David Katzenstein
Hloniphile Mthiyane
Johannes Viljoen
Prevashinee Padayachee
Siva Danaviah
Sureshnee Pillay
Tobias F Rinke de Wit
Tulio De Oliveira
P2860
P356
10.3791/51242
P577
2014-03-30T00:00:00Z